Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Anus Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Anus Diseases

Rectal Diseases

Neoplasms, Squamous Cell

Anal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Fluorouracil

Mitomycins

Mitomycin

Panitumumab

Antineoplastic Agents, Immunological

5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10

Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²

radiochemotherapy

Véronique VENDRELY, MD

Treatment is based on radiochemotherapy for locally advanced tumours. The objective of treatment is to provide a cure without resorting to abdominoperineal amputation, while preserving sphincter function.

The prognosis is mainly related to tumour size and lymph node invasion. The large majority of patients do not show any spread remote from the tumour at the time of diagnosis (2).

Recurrences are mainly of a local/regional nature and require abdominoperineal amputation. This type of intervention is not always possible or complete, which then gives rise to the particularly distressing risk of local progression, with survival at 3 years of approximately 30% (3).

It is therefore very important to achieve a complete and permanent tumour response from initial treatment with radiochemotherapy.

Furthermore, the use of an anti-EGFR antibody in combination with exclusive radiotherapy in ENT cancer was able to increase recurrence-free survival and overall survival in these patients. These data are in favour of the use of a combination of chemotherapy and anti-EGFR antibodies in epidermoid cancer of the anus.

Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus

Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus

Federation Francophone de Cancerologie Digestive

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus	NCT01581840	Epidermoid Carc... Anus	radiochemothera... Panitumumab	18 Years -	Federation Francophone de Cancerologie Digestive
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus	NCT01581840	Epidermoid Carc... Anus	radiochemothera... Panitumumab	18 Years -	Federation Francophone de Cancerologie Digestive
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus	NCT01581840	Epidermoid Carc... Anus	radiochemothera... Panitumumab	18 Years -	Federation Francophone de Cancerologie Digestive

Spots Global Cancer Trial Database for mitomycine

Every month we try and update this database with for mitomycine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mitomycine

Every month we try and update this database with for mitomycine cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mitomycine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.